Prot #CA224-098: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma (RELATIVITY 098)

Project: Research project

Project Details

StatusActive
Effective start/end date6/3/22 → 6/3/25

Funding

  • Bristol-Myers Squibb Company (Prot #CA224-098)